NCI’s publicly announced move to create an ad hoc working group that would review the feasibility and viability of the TMIST trial threatens to undercut this trial, said Mitchell Schnall, co-chair of ECOG-ACRIN Cancer Research Group, the group conducting the study.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
